The role of liposomes in clinical nanomedicine development. What now? Now what?
Publication date
2020-02
Authors
Crommelin, Daan J.A.
van Hoogevest, Peter
Storm, Gert
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
The rapid rise in interest in 'nanomedicines' in the academic world over the last twenty years and the claims of success led to calls for reflection. The main body of text of this Commentary will be on answering the question: 'where to go with nanomedicines'? Research priorities for the future will be outlined based on experience with the most successful nanomedicines family within the broad field of nanomedicine so far: liposomes. An analysis of currently clinically tested, approved and marketed liposome-drug combinations provides these insights.
Keywords
Liposomes, Nanomedicines, Clinical trials, Taverne
Citation
Crommelin, D J A, van Hoogevest, P & Storm, G 2020, 'The role of liposomes in clinical nanomedicine development. What now? Now what?', Journal of controlled release : official journal of the Controlled Release Society, vol. 318, pp. 256-263. https://doi.org/10.1016/j.jconrel.2019.12.023